Joint Symposium ESMO-EORTC-EACR: What has melanoma taught us about targeted therapies and immunotherapy?
Where next in targeted therapies and melanoma?
Date
09 Oct 2016Session
Joint Symposium ESMO-EORTC-EACR: What has melanoma taught us about targeted therapies and immunotherapy?Presenters
Richard MaraisAuthors
R. MaraisAuthor affiliations
- Molecular Oncology, Cancer Research UK Manchester Institute, M20 4BX - Manchester/GB
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
Introduction
Presenter: Rolf A. Stahel
Session: Joint Symposium ESMO-EORTC-EACR: What has melanoma taught us about targeted therapies and immunotherapy?
Resources:
Webcast
Where next in immunotherapy and melanoma?
Presenter: Paolo Ascierto
Session: Joint Symposium ESMO-EORTC-EACR: What has melanoma taught us about targeted therapies and immunotherapy?
Resources:
Slides
Webcast
Patient advocacy initiatives
Presenter: Bettina Ryll
Session: Joint Symposium ESMO-EORTC-EACR: What has melanoma taught us about targeted therapies and immunotherapy?
Resources:
Slides
Webcast